TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20538838
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg
Study: 20538838
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 600 mg (healthy control)
Study: 16521032
Drug: Cocaine infusions
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine infusions (0, 8, 16, and 32 mg/70 kg)
Study: 16521032
Drug: Cocaine infusions
Normalized name: Cocaine
DrugBank: Cocaine (DB00907)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine infusions (16 mg)
Study: 12724276
Drug: VCY2 antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: VCY2 antibody
Study: 9505982
Drug: 15 mg
Normalized name: papain 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg hydrocodone bitartrate with 400 mg ibuprofen
Study: 3516291
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration of apomorphine
Study: 3516291
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of apomorphine
Study: 29456025
Drug: Control (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (weekly e-mail newsletter)
Study: 24812891
Drug: Kuanxiong Aerosol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kuanxiong Aerosol (KA), sublingual spray 0.6 mL three times during angina attack
Study: 24812891
Drug: Nitroglycerin Tablet
Normalized name: nitroglycerin Sublingual Tablet
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin Tablet (NT), 0.5 mg sublingually dissolved during angina attack
Study: 24812891
Drug: Nitroglycerin Tablet
Normalized name: nitroglycerin Sublingual Tablet
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin Tablet (NT)
Study: 23654012
Drug: Medicamentous therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medicamentous therapy (Diklofenak 100 mg, 2 tablets per day)
Study: 18797179
Drug: AIC immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AIC immunotherapy (6 escalating doses of AIC 0.06-12 microg; n = 12)
Study: 8635184
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of tolcapone
Study: 8635184
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of tolcapone
Study: 2169213
Drug: 150 IU.kg‐1.day‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 IU.kg‐1.day‐1 heparin (group HEP)
Study: 2169213
Drug: 1.2 mg.kg‐1.day‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 mg.kg‐1.day‐1 enoxaparin (group ENX)
Study: 2169213
Drug: 0.8 mg.kg‐1.day‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg.kg‐1.day‐1 enoxaparin with 5 ng.kg‐1.min‐1 prostaglandin I2 (group ENX and PGI2)
Study: 27444991
Drug: Continuous saline
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous saline bladder irrigation (CSBI) at 2000 mL/h for the first 1 hour, then 1000 mL/h for 2 hours, followed by 500 mL/h for 15 hours
Study: 25976647
Drug: Group 1:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1: 20 mg per day lutein (L), 0.86 mg per day zeaxanthin (Z); Ultra Lutein
Study: 25976647
Drug: Group 2:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2: 10 mg per day meso-zeaxanthin (MZ), 10 mg per day L, 2 mg per day Z; Macushield; Macuhealth
Study: 25976647
Drug: Group 3:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 3: 17 mg per day MZ, 3 mg per day L, 2 mg per day Z
Study: 17083064
Drug: Enalapril (520
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (520 mg/d)
Study: 10977396
Drug: Vaccination with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccination with the 23‐valent pneumococcal polysaccharide vaccine
Study: 10977396
Drug: No vaccination
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vaccination and treatment
Study: 8783051
Drug: Colgate 0-6
Normalized name: Colgate
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colgate 0-6 gel
Study: 1731288
Drug: Routine weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine weekly cervical examinations at term (from 37 weeks until delivery)
Study: 1731288
Drug: Routine weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Routine weekly cervical examinations at term
Study: 30565892
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 supplementation (50,000 IU monthly)
Study: 25239216
Drug: Control (CON)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (CON) group (placebo solution)
Study: 20157677
Drug: Preparation walls
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation walls (pulpal, axial, gingival)
Study: 17306498
Drug: New agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: New agents for treating castration-resistant prostate cancer
Study: 11879139
Drug: Topical unoprostone
Normalized name: unoprostone
DrugBank: Unoprostone (DB06826)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical unoprostone
Study: 11879139
Drug: ET-1 administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ET-1 administration
Study: 10673968
Drug: Patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient treatment preferences
Study: 2138477
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg Adriamycin i.v. weekly (Awkly)
Study: 2138477
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg 4‐epidoxorubicin biweekly (EPIbiwkly)
Study: 6766411
Drug: Phosphate infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate infusions (62 ± 5 mmol sodium phosphate)
Study: 6766411
Drug: Standardized conventional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized conventional treatment alone
Study: 29974963
Drug: Omalizumab 300
Normalized name: OMALIZUMAB 300MG/2ML INJ,SOLN,SYR,2ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omalizumab 300 mg administered subcutaneously every 4 weeks for 12 weeks
Study: 26669545
Drug: Immediate post-extractive
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post-extractive implants
Study: 28327692
Drug: Immediate-delayed implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-delayed implants at 6 weeks
Study: 28327692
Drug: Delayed implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implants after 4 months
Study: 25821849
Drug: High-fluoride dentifrice
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-fluoride dentifrice (5000 µg F/g)
Study: 25821849
Drug: Conventional fluoride
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional fluoride dentifrice (1100 µg F/g)
Study: 23543359
Drug: Prime Time
Normalized name: ZINC OXIDE 10.49 g in 100 g / TITANIUM DIOXIDE 3.13 g in 100 g TOPICAL LOTION [Prime Time Daily Protecting Primer SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prime Time intervention (dose-response analysis)
Study: 19848209
Drug: Oral hypoglycemic
Normalized name: ORAL HYPOGLYCEMIC AGENTS,ORAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hypoglycemic drugs (glipizide, pioglitazone, metformin) and antihypertensive drug (nifedipine)
Study: 17489878
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg telmisartan/day
Study: 17489878
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg irbesartan/day
Study: 17489878
Drug: Fasting plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting plasma insulin (FPI)
Study: 11506246
Drug: Steroids (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids (oral prednisone 1.0 mg/Kg/day for 2 months, tapered by 0.2 mg/Kg/day every month) plus ramipril (2.5 mg/day for one month, increased by 1.25 mg/day every month)
Study: 11506246
Drug: Steroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroids plus ramipril
Study: 9754987
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg alone
Study: 9754987
Drug: Caffeine 150
Normalized name: caffeine 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 150 mg alone
Study: 9754987
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg with zolpidem
Study: 9754987
Drug: Zolpidem 10
Normalized name: zolpidem 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem 10 mg with caffeine 250 mg
Study: 8116706
Drug: Prophylactic penicillin
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic penicillin (1 million units of benzylpenicillin intravenously every 4 hours followed by 250 mg of potassium phenoxymethyl penicillin orally twice daily)
Study: 146511
Drug: Zinc sulphate
Normalized name: Zinc sulphate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulphate (0.4 g daily)
Study: 23644090
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy (rosuvastatin 40 mg daily)
Study: 23644090
Drug: Standard-of-care lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care lipid-lowering therapy
Study: 21325901
Drug: Intrathecal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal meperidine 12.5 mg (M1)
Study: 21325901
Drug: Intrathecal meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal meperidine 25 mg (M2)
Study: 21325901
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (M0) with bupivacaine 0.5% (10 mg)
Study: 21325901
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of meperidine (M1 and M2)
Study: 16433203
Drug: 4-shot allergy
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-shot allergy vaccine (Pollinex Quattro) containing appropriate allergoids (grass/rye and/or mugwort) adsorbed to L-tyrosine plus a Th1 adjuvant, monophosphoryl lipid A (MPL)
Study: 16433203
Drug: 4-shot allergy
Normalized name: ChoreMate One-Shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-shot allergy vaccine (Pollinex Quattro)
Study: 16433203
Drug: Control challenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control challenges (similar pollen vaccine without MPL and a tree pollen vaccine with and without MPL)
Study: 12877821
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 microg twice daily in addition to beclomethasone 500 microg twice daily
Study: 12877821
Drug: Beclomethasone 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone 1000 microg twice daily and placebo
Study: 9950912
Drug: TNFR:Fc (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR:Fc (6 mg/m2)
Study: 26115589
Drug: Carbohydrate‐electrolyte gels
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate‐electrolyte gels (0.7±0.1gkg(‐1) BM)
Study: 26115589
Drug: Energy-free placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Energy-free placebo gels
Study: 25310201
Drug: Lisdexamfetamine dimesylate
Normalized name: Lisdexamfetamine Dimesylate
DrugBank: Lisdexamfetamine (DB01255)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Lisdexamfetamine dimesylate (LDX) 50, 70, 100, 150, 200, and 250 mg daily for 5 days
Study: 19696435
Drug: FFW-L/NBLI and
Approvals — FDA: no, EMA: no, PMDA: no
Description: FFW-L/NBLI and NBLI/FFW-L (combined intervention groups)
Study: 16141467
Drug: Sodium selenite
Normalized name: Sodium selenite
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Sodium selenite (1,000 microg administered intravenously or orally daily for 3 weeks)
Study: 10102147
Drug: Zinc supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc supplementation (14.2 mg elemental zinc for first 417 patients and 40 mg for remaining 273 patients) for 15 days
Study: 2185023
Drug: Carbochromen (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbochromen (0.125 mg kg‐1 min‐1 for 40 min i.v.)
Study: 2185023
Drug: Dipyridamole (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.05 mg kg‐1 min‐1 for 10 min i.v.)
Study: 399859
Drug: Continuous salbutamol
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous salbutamol tablets
Study: 399859
Drug: Intermittent salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent salbutamol tablets
Study: 30982716
Drug: No pain
Normalized name: Biochemistry Heel No Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: No pain medication
Study: 31299447
Drug: Active placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active placebo nasal spray with expectancy-modifying instructions (Protection: the spray protects from experiencing negative emotions)
Study: 31299447
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Sensitization: the spray sensitizes to negative emotions)
Study: 31299447
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Placebo: the spray is a placebo)
Study: 31299447
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Control: no nasal spray)
Study: 28547075
Drug: Suprascapular nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suprascapular nerve (SSN)‐pulsed radiofrequency (RF) therapy
Study: 28547075
Drug: Both PBMT
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both PBMT and SSN-pulsed RF therapy
Study: 21599941
Drug: Specific physiotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific physiotherapy treatment (10 sessions over 10 weeks)
Study: 21599941
Drug: Specific physiotherapy
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific physiotherapy treatment
Study: 12817519
Drug: ICL670 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICL670 2.5 to 80 mg/kg
Study: 12817519
Drug: ICL670 40-
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICL670 40- and 80-mg/kg dose levels
Study: 8656257
Drug: Reintroduction chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reintroduction chemotherapy
Study: 8656257
Drug: Reintroduction chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reintroduction chemotherapy for women aged > or = 40 years
Study: 6340601
Drug: Ceftazidime 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1.5 g daily
Study: 6340601
Drug: Ceftazidime 3
Normalized name: ceftazidime 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 3 g daily
Study: 31238907
Drug: Internet-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive-behavioral treatment (9 sessions)
Study: 28121935
Drug: Citicoline therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citicoline therapy at 0.6 g/d for 1 year
Study: 28121935
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no central nervous system drugs except sleeping pills and antidepressants)
Study: 16685052
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (GFJ) 240 mL with felodipine 10 mg
Study: 16685052
Drug: Orange juice
Normalized name: Orange juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange juice 240 mL with felodipine 10 mg
Study: 16685052
Drug: Furanocoumarin-free grapefruit
Normalized name: GRAPEFRUIT
DrugBank: Grapefruit (DB10534)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furanocoumarin-free grapefruit juice 240 mL with felodipine 10 mg
Study: 15474877
Drug: Sodium-restricted diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium-restricted diet (2000 to 2400 mg/d) with restriction of total fluids to 1.5 L/d
Study: 15474877
Drug: Traditional medical
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional medical treatment and general nutritional recommendations
Study: 10980174
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg once daily for 10 days
Study: 9892527
Drug: Polymyxin B-immobilized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymyxin B-immobilized fibre (PMX-F) treatment
Study: 2738584
Drug: Subcutaneous hepatitis
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous hepatitis B vaccine
Study: 21364482
Drug: Carbohydrate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate and protein solution (CHO + P) providing 0.49 and 0.16 g·kg(‐1)·h(‐1)
Study: 21364482
Drug: Carbohydrate solution
Normalized name: phosphorated carbohydrate solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate solution (CHO) providing 0.49 g·kg(‐1)·h(‐1)
Study: 21364482
Drug: Carbohydrate and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate and protein solution (CHO + P)
Study: 11935108
Drug: Sherbrooke model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sherbrooke model (combination of clinical-rehabilitation and occupational interventions)
Study: 10412300
Drug: Systemic palliative
Normalized name: Various pain palliation radiopharmaceuticals
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic palliative chemotherapy with 5-fluorouracil and leucovorin
Study: 7549760
Drug: Trained health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained health workers (HWs) conducting oral visual inspections
Study: 2247650
Drug: Standard 10
Normalized name: grass pollen-timothy, standard 10,000 bioequiv. allergy unit/mL INJECTION VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard 10 Gy single dose TBI
Study: 7470371
Drug: Nicotine 500
Normalized name: Nicotine 500 microgram/actuation nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 500 μg
Study: 7470371
Drug: Nicotine 750
Normalized name: niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine 750 μg
Study: 7470371
Drug: Range of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Range of nicotine doses from 12.5 to 800 μg
Study: 6403254
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy consisting of cis‐platinum 40 mg/m2 IV on day 1, adriamycin 40 mg/m2 IV on day 1, and hexamethylmelamine 150 mg/m2 PO on days 2‐10 up to a maximum of 200 mg on a 4‐weekly cycle.
Study: 6403254
Drug: Moderate‐dose cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate‐dose cyclophosphamide alone 40 mg/kg given IV intermittently every 3 weeks.
Study: 28065179
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (FO) supplementation (1.5 g/d n-3 LCPUFA)
Study: 7068895
Drug: Habit reversal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Habit reversal treatment
Study: 21664779
Drug: Neoadjuvant endocrine
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant endocrine therapy (NAE)
Study: 20051135
Drug: MF‐DPI 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF‐DPI 400 microg once‐daily in the evening
Study: 20051135
Drug: MF‐DPI 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF‐DPI 200 microg twice‐daily
Study: 20051135
Drug: Self-reports for
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-reports for MF‐DPI 400 microg once‐daily
Study: 20051135
Drug: Self-reports for
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-reports for MF‐DPI 200 microg twice‐daily
Study: 17942035
Drug: Sulpiride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (50 mg/8 h)
Study: 17118597
Drug: Sulpiride (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride (50 mg/8 h) plus Hydroxyzine (25 mg/12 h)
Study: 16244511
Drug: General program
Approvals — FDA: no, EMA: no, PMDA: no
Description: General program of psychomotor therapy (different forms of physical exercises and relaxation training)
Study: 11838838
Drug: keliximab 40
Normalized name: Galiximab
DrugBank: Galiximab (DB04901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: keliximab 40 mg twice weekly (bw)
Study: 11838838
Drug: keliximab 80
Normalized name: Galiximab
DrugBank: Galiximab (DB04901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: keliximab 80 mg bw
Study: 11838838
Drug: keliximab 140
Normalized name: Galiximab
DrugBank: Galiximab (DB04901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: keliximab 140 mg bw
Study: 11838838
Drug: keliximab 240
Normalized name: Galiximab
DrugBank: Galiximab (DB04901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: keliximab 240 mg once weekly (ow)
Study: 11838838
Drug: keliximab 120
Normalized name: Galiximab
DrugBank: Galiximab (DB04901)
Approvals — FDA: no, EMA: no, PMDA: no
Description: keliximab 120 mg bw
Study: 2405733
Drug: Oral caffeine
Normalized name: caffeine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral caffeine (300 mg)
Study: 11216966
Drug: Oral anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulant therapy
Study: 31427637
Drug: Nurse-led follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-led follow-up and medical titration by telephone to reach set intervention targets
Study: 26295379
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care intervention for chronic pain; details on dosage and duration not specified.